Company intelligence / Profile preview

Viscient Biosciences

San Diego, California, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Viscient’s lead compound for NASH, discovered using its proprietary 3D bioprinted human tissue models, has shown strong preclinical efficacy by reducing fibrosis and correlating well with clinical outcomes of known drugs. The company claims its model accurately predicts both successes and failures among clinical compounds tested to date. The lead candidate has demonstrated good tolerability and histological improvement in preclinical studies. Clinical entry was anticipated for 2024.

Therapeutic areas: Gastroenterology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Viscient Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viscient Biosciences.

Explore the full profile